GlaxoSmithKline (GSK) has released its fourth-quarter 2018 results, reporting prescription drug sales of £4.8 billion – a 6% increase on the prior year period – and profit of £1.4 billion, marking an increase of £442 million.Original Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.